Distant lymph nodes serve as pools of <scp>Th</scp>1 cells induced by neonatal <scp>BCG</scp> vaccination for the prevention of asthma in mice

Zhang, G; Wang, P; Qiu, Zhangwei; Qin, Xuejun; Lin, Xiang; Li, Na; Huang, Huaqiong; Liu, H; Huang, Wen; Chen, Z; Zhao, Huanyu; Li, Wen; Shen, Huahao

doi:10.1111/all.12099

Cited by 16 publications

(19 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We further demonstrated that BCG vaccination effectively attenuated chronic OVA challenge‐induced airway remodelling in mice . The mechanisms of this protective effect were most likely due to an induced Th1 response by BCG . Interestingly, these BCG‐induced Th1 cells mainly resided in draining lymph nodes and had the potential for proliferation and differentiation.…”

Section: Basic Science Researchmentioning

confidence: 72%

“…Interestingly, these BCG‐induced Th1 cells mainly resided in draining lymph nodes and had the potential for proliferation and differentiation. Upon OVA challenges, these Th1 cells were able to migrate into the local airways to inhibit the allergic Th2 immune response . Studies from other groups also demonstrated the protective role of BCG in asthmatic inflammation .…”

Section: Basic Science Researchmentioning

confidence: 94%

“…Upon OVA challenges, these Th1 cells were able to migrate into the local airways to inhibit the allergic Th2 immune response. 73 Studies from other groups also demonstrated the protective role of BCG in asthmatic inflammation. 74 Dermatophagoides pteronyssinus 2 recombined BCG also dramatically inhibited airway inflammation in allergic mice.…”

Section: Immunological Approachesmentioning

confidence: 94%

“…72 The mechanisms of this protective effect were most likely due to an induced Th1 response by BCG. 73 Interestingly, these BCG-induced Th1 cells mainly resided in draining lymph nodes and had the potential for proliferation and differentiation. Upon OVA challenges, these Th1 cells were able to migrate into the local airways to inhibit the allergic Th2 immune response.…”

Section: Immunological Approachesmentioning

confidence: 99%

See 3 more Smart Citations

Asthma research in China: A five‐year review

2013

View full text Add to dashboard Cite

Asthma is one of the most common chronic diseases worldwide with increasing morbidity. China has the largest asthmatic population and is one of the countries with the highest asthma mortality. Fortunately, asthma research in China, both clinical and scientific, has developed markedly over the past few years. This has resulted in significant increases in our understanding of Chinese asthma prevalence, risk factors, control status, pathogenesis, and new prevention or treatment strategies. In this review, the major achievements of asthma research in China from 2008 to 2012 are summarized.

show abstract

Section: Basic Science Researchmentioning

confidence: 72%

Section: Basic Science Researchmentioning

confidence: 94%

Section: Immunological Approachesmentioning

confidence: 94%

Section: Immunological Approachesmentioning

confidence: 99%

See 2 more Smart Citations

Asthma research in China: A five‐year review

2013

View full text Add to dashboard Cite

show abstract

“…BCG possesses several attributes that make it a highly favorable candidate for development as a recombinant vaccine vector. These include its ability (i) to express transgenic antigens from pathogens, such as HIV, (ii) to induce strong T-cell responses associated with the release of gamma interferon (IFN-␥) and other Th 1 cytokines, and (iii) to generate T-cell responses specific for transgenic antigens, which can ultimately be increased by heterologous boost vaccination (1)(2)(3)(4)(5)(6)(7)(8). The aforementioned responses are generated with high doses of recombinant BCG (rBCG).…”

mentioning

confidence: 99%

Role for Gr-1⁺Cells in the Control of High-Dose Mycobacterium bovis Recombinant BCG

Panas

Letvin

2014

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

Mycobacterium bovis bacillus Calmette-Guérin (BCG) is an attractive target for development as a live vaccine vector delivering transgenic antigens from HIV and other pathogens. Most studies aimed at defining the clearance of BCG have been performed at doses between 10 2 and 10 4 CFU. Interestingly, however, recombinant BCG (rBCG) administered at doses of >10 6 CFU effectively generates antigen-specific T-cell responses and primes for heterologous boost responses. Thus, defining clearance at high doses might aid in the optimization of rBCG as a vector. In this study, we used bioluminescence imaging to examine the kinetics of rBCG transgene expression and clearance in mice immunized with 5 ؋ 10 7 CFU rBCG expressing luciferase. Similar to studies using low-dose rBCG, our results demonstrate that the adaptive immune response is necessary for long-term control of rBCG beginning 9 days after immunizing mice. However, in contrast to these reports, we observed that the majority of mycobacterial antigen was eliminated prior to day 9. By examining knockout and antibody-mediated depletion mouse models, we demonstrate that the rapid clearance of rBCG occurs in the first 24 h and is mediated by Gr-1 ؉ cells. As Gr-1 ؉ granulocytes have been described as having no impact on BCG clearance at low doses, our results reveal an unappreciated role for Gr-1 ؉ neutrophils and inflammatory monocytes in the clearance of high-dose rBCG. This work demonstrates the potential of applying bioluminescence imaging to rBCG in order to gain an understanding of the immune response and increase the efficacy of rBCG as a vaccine vector. Mycobacterium bovis bacillus Calmette-Guérin (BCG) is an attenuated mycobacterial vaccine administered to newborns for the prevention of childhood miliary tuberculosis. BCG possesses several attributes that make it a highly favorable candidate for development as a recombinant vaccine vector. These include its ability (i) to express transgenic antigens from pathogens, such as HIV, (ii) to induce strong T-cell responses associated with the release of gamma interferon (IFN-␥) and other Th 1 cytokines, and (iii) to generate T-cell responses specific for transgenic antigens, which can ultimately be increased by heterologous boost vaccination (1-8). The aforementioned responses are generated with high doses of recombinant BCG (rBCG). Specifically, rBCG administered to mice at a dose equal to 10 6 CFU rapidly induces the development of transgene product-specific T cells, a response not observed using lower doses of 10 3 to 10 6 CFU (9-11). Furthermore, rBCG doses of Ͼ10 7 CFU induce detectable primary T-cell responses directed against the foreign transgenic epitope in rhesus macaque studies, responses that are not observed at lower doses (5,12).Despite the fact that transgene-product specific T cells are generated in response to high doses of rBCG, very few experiments have been performed to determine the clearance of high-dose BCG. Instead, experiments determining the clearance of BCG have been done using lower doses of...

show abstract

Novel T‐cell epitopes on Schistosoma japonicum SjP40 protein and their preventive effect on allergic asthma in mice

Ren

Yang

et al. 2016

Eur J Immunol

View full text Add to dashboard Cite

Allergic asthma is a chronic inflammatory disease mediated by Th2 cell immune responses. Currently, immunotherapies based on immune deviation are attractive, preventive, and therapeutic strategies for asthma. Many studies have shown that intracellular bacterial infections such as mycobacteria and their components can suppress asthmatic reactions by enhancing Th1 responses, while helminth infections and their proteins can inhibit allergic asthma via immune regulation. However, some helminth proteins such as SmP40, the major egg antigen of Schistosoma mansoni, are found as Th1 type antigens. Using a panel of overlapping peptides, we identified T-cell epitopes on SjP40 protein of Schistosoma japonicum, which can induce Th1 cytokine and inhibit the production of Th2 cytokines and airway inflammation in a mouse model of allergic asthma. These results reveal a novel form of immune protective mechanism, which may play an important role in the modulating effect of helminth infection on allergic asthmatic reactions.Keywords: Asthma r peptides r Schistosoma japonicum r SjP40 r Th1 epitope Additional supporting information may be found in the online version of this article at the publisher's web-site IntroductionAllergic asthma is a chronic airway disorder characterized by reversible airflow obstruction, increased allergen-specific IgE production, and predominant eosinophilic airway inflammation [1]. From immunology point of view, the pathology in asthma occurs Correspondence: Dr. Peimei Liu e-mail: liupeimei63@126.com as a consequence of increased Th2 type immune responses, especially overproduction of IL-4, IL-5, and IL-13 by allergen-specific CD4 + T helper (Th) cells [2,3].The prevalence of allergy and asthma has increased markedly over the past decades world-wide, not only in developed but also developing areas [4,5]. The reason for this dramatic increase * These authors contributed equally to this work. Eur. J. Immunol. 2016Immunol. . 46: 1203Immunol. -1213 remains unclear. It was believed that an insufficient stimulation of the Th1 responses due to limited exposure to bacterial and viral pathogens could not counterbalance the expansion of Th2 responses resulting in predisposition of allergy. However, the distorted Th1/Th2 balance could not explain the simultaneous increase in several Th1-mediated auto-immune diseases together with the increase in allergic disorders in the same countries. Then it is suggested that more vital microbial exposures, such as chronic infections (helminthes) and commensals seem to be important to prevent the development of hyperinflammatory responses [6]. Therefore, the induction of a strong regulatory network (tolerogenic DC, Treg, Breg, Tr-1, Tr-3) and Th1 responses by these microbes is an important factor in controlling the diseases.Immunotherapy based on immune deviation is an effective strategy to treat or prevent allergic asthma. Live and dead bacteria, parasite, or bacterial components such as purified protein derivative from Mycobacterium tuberculosis have shown potential to prote...

show abstract

Distant lymph nodes serve as pools of Th1 cells induced by neonatal BCG vaccination for the prevention of asthma in mice

Abstract: These data demonstrate that ILN serves as a 'weapon' pool of Th1 cells following BCG vaccination, and these cells are ready for the migration into the inflamed lungs upon the allergen challenge, thereby inhibiting allergen-induced airway disorder.

Cited by 16 publications

References 31 publications

Asthma research in China: A five‐year review

Asthma research in China: A five‐year review

Role for Gr-1⁺Cells in the Control of High-Dose Mycobacterium bovis Recombinant BCG

Novel T‐cell epitopes on Schistosoma japonicum SjP40 protein and their preventive effect on allergic asthma in mice

Contact Info

Product

Resources

About

Distant lymph nodes serve as pools of Th1 cells induced by neonatal BCG vaccination for the prevention of asthma in mice

Abstract: These data demonstrate that ILN serves as a 'weapon' pool of Th1 cells following BCG vaccination, and these cells are ready for the migration into the inflamed lungs upon the allergen challenge, thereby inhibiting allergen-induced airway disorder.

Cited by 16 publications

References 31 publications

Asthma research in China: A five‐year review

Asthma research in China: A five‐year review

Role for Gr-1+Cells in the Control of High-Dose Mycobacterium bovis Recombinant BCG

Novel T‐cell epitopes on Schistosoma japonicum SjP40 protein and their preventive effect on allergic asthma in mice

Contact Info

Product

Resources

About

Role for Gr-1⁺Cells in the Control of High-Dose Mycobacterium bovis Recombinant BCG